Cardio Catch-Up: Procyrion Raises Nearly $60M As Aortix Creeps Closer To Clinic

 
• By Barnaby Pickering

The Houston-based cardiovascular device developer has secured renewed support from its investors to fund its pivotal trial of Aortix, a device designed to treat patients suffering from often-fatal, difficult to treat cardiorenal syndrome.  

Four and a half years after its Aortix percutanteous mechanical circulatory support device received US Food and Drug Administration breakthrough designation, Procyrion has raised $57.7m in a series E funding round to support a pivotal trial.

According to Procyrion, the money raised will go towards its 268-patient, 45-center pivotal investigational device exemption DRAIN HF trial.

More from Financing

More from Business